신장 바이오마커 시장 : 규모, 점유율, 동향 분석, 바이오마커별, 진단 기법별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Renal Biomarkers Market Summary

The global renal biomarkers market size was estimated at USD 1,530.0 million in 2024 and is expected to reach USD 3,161.4 million by 2033, growing at a CAGR of 8.54% from 2025 to 2033. The rising prevalence of kidney disease particularly chronic kidney disease (CKD) and acute kidney injury (AKI) along with the urgent clinical need for earlier and more nuanced detection beyond conventional measures.

CKD often remains asymptomatic until advanced stages, and biomarkers that can reveal subclinical pathology or early injury are of growing interest. In the U.S., an estimated 35.5 million adults have chronic kidney disease (CKD), and a significant number are unaware of their condition. Globally, CKD affects around 850 million people, which is approximately 9% of the adult population. A 2024 study projects that by 2032, nearly 125 million people across eight major countries will have advanced CKD, a 25% increase since 2022. In April 2024, AstraZeneca's IMPACT CKD modeling study projected that by 2032, as many as 16.5% of the population across eight countries could be affected by chronic kidney disease (CKD), with advanced-stage cases potentially increasing by up to 59.3%. The findings, presented at the 2024 ISN World Congress of Nephrology (WCN'24) in Buenos Aires, underscored the escalating global health challenge posed by CKD and emphasized its significant economic and environmental consequences. The large and growing base of kidney disease patients ensures a continually rising demand for more sensitive, specific, and multiplex biomarker assays. In addition, co-morbidities such as diabetes, hypertension, and aging populations further exacerbate kidney stress, pushing clinicians and payers to adopt advanced biomarkers (e.g. NGAL, KIM-1, cystatin C) earlier in the disease continuum to improve prognostics, therapy stratification, and monitoring. The high rate of undiagnosed early CKD (sometimes up to 90 % of cases go unnoticed until functional decline) underscores the latent market potential for tools that reliably flag early damage before conventional metrics (eGFR, creatinine) deviate significantly.

One of the most compelling opportunities in the renal biomarker landscape lies in emerging markets-Asia, Latin America, Africa where rising incidence of hypertension, diabetes, and aging populations is intensifying the renal disease burden, yet diagnostic infrastructure remains underdeveloped. As diagnostics penetration is still relatively low in many of these geographies, the entry of affordable, point-of-care biomarker platforms offers a high-growth niche. For example, Sphingotec's collaborations (e.g. with Beckman Coulter) to release penKid assays on standard clinical lab platforms reflect how a biomarker originally confined to research can scale into broader clinical adoption. (See news of licensing and launch of penKid in central labs) The capacity to deploy multiplex panels, low-volume assays, or simpler rapid tests in decentralized settings could help bridge diagnostic gaps in underserved regions.

Meanwhile, platform diversity is growing enzyme-linked immunosorbent assays (ELISA) still command a significant share, but more sensitive chemiluminescent immunoassays, multiplex panels, mass spectrometry (LC-MS), microfluidics, and point-of-care immunodiagnostic devices are gaining traction. For instance, the penKid assay's adoption on Beckman Coulter immunoassay platforms exemplifies how a novel biomarker can be integrated lab workflows. In research settings, microfluidic and multi-omics platforms will support novel discovery and multiplex panels opening scope for biomarker companies to offer value-added analytics, software, and interpretation services.

Global Renal Biomarkers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global renal biomarkers market based on biomarker, diagnostic technique, end use, and region:

• Biomarkers Outlook (Revenue, USD Million, 2021 - 2033)
• Kits and reagents
• Functional Biomarkers
  • Serum Creatinine
  • Blood Urea Nitrogen (BUN)
  • Estimated Glomerular Filtration Rate (eGFR)
• Upregulated Proteins
  • Kidney Injury Molecule-1 (KIM-1)
  • Neutrophil Gelatinase-Associated Lipocalin (NGAL)
  • Cystatin C
  • Interleukin-18 (IL-18)
  • Others
• Other Novel Biomarkers
  • microRNA biomarkers
  • Proteomic/metabolomic markers
• Diagnostic technique/Platform Outlook (Revenue, USD Million, 2021 - 2033)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Immunoassays
• Clinical Chemistry Assays
• Point-of-Care Testing (POCT) Devices
• Molecular Diagnostics
• Other Emerging Platforms
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Renal Biomarkers Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Biomarkers Segment
    • 1.1.1.2. Diagnostic Technique/Platform Segment
    • 1.1.1.3. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Renal Biomarkers Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Renal Biomarkers Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
    • 3.3.1.1. Rising prevalence of kidney diseases:
    • 3.3.1.2. Government Initiatives and Health Awareness Programs
    • 3.3.1.3. Technological advancements in kidney diagnostics
  • 3.3.2. Market restraint analysis
    • 3.3.2.1. High cost of diagnostics test
    • 3.3.2.2. Limited availability of trained personnel to perform and interpret biomarker tests
• 3.4. Global Biomarker-Based Immunoassays Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
  • 3.4.2. PESTEL Analysis

Chapter 4. Renal Biomarkers Market: Biomarkers Estimates & Trend Analysis

• 4.1. Renal Biomarkers Market: Biomarkers Movement Analysis
• 4.2. Kits and assays
  • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.3. Reagents
  • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Services
  • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Functional Biomarkers
  • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Serum Creatinine
    • 4.5.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Blood Urea Nitrogen (BUN)
    • 4.5.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. Estimated Glomerular Filtration Rate (eGFR)
    • 4.5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Upregulated Proteins
  • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Kidney Injury Molecule-1 (KIM-1)
    • 4.6.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.3. Neutrophil Gelatinase-Associated Lipocalin (NGAL)
    • 4.6.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.4. Cystatin C
    • 4.6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.5. Interleukin-18 (IL-18)
    • 4.6.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.6. Others
    • 4.6.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Other Novel Biomarkers
  • 4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7.2. microRNA biomarkers
    • 4.7.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7.3. Proteomic/metabolomic markers
    • 4.7.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Renal Biomarkers Market: Diagnostic Technique/Platform Estimates & Trend Analysis

• 5.1. Renal Biomarkers Market: Diagnostic Technique/Platform Movement Analysis
• 5.2. Enzyme-Linked Immunosorbent Assay (ELISA)
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.3. Molecular Diagnostics
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Immunoassays
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Clinical Chemistry Assays
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Point-of-Care Testing (POCT) Devices
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Other Emerging Platforms
  • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Renal Biomarkers Market: End Use Estimates & Trend Analysis

• 6.1. Renal Biomarkers Market: End Use Movement Analysis
• 6.2. Hospitals and clinics
  • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.3. Diagnostics Laboratories
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Academic & Research Institutes
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Pharmaceutical & Biotechnology Companies
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Renal Biomarkers Market: Regional Business Analysis

• 7.1. Regional Market Snapshot
• 7.2. North America
  • 7.2.1. North America Renal Biomarkers Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.2.2.2. Key Country Dynamics
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. Reimbursement Scenario
    • 7.2.2.5. Competitive Scenario
  • 7.2.3. Canada
    • 7.2.3.1. Canada Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.2.3.2. Key Country Dynamics
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Reimbursement Scenario
    • 7.2.3.5. Competitive Scenario
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.2.4.2. Key Country Dynamics
    • 7.2.4.3. Regulatory Framework
    • 7.2.4.4. Reimbursement Scenario
    • 7.2.4.5. Competitive Scenario
• 7.3. Europe
  • 7.3.1. Europe Renal Biomarkers Market, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.2.2. Key Country Dynamics
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. Reimbursement Scenario
    • 7.3.2.5. Competitive Scenario
  • 7.3.3. Germany
    • 7.3.3.1. Germany Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.3.2. Key Country Dynamics
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Reimbursement Scenario
    • 7.3.3.5. Competitive Scenario
  • 7.3.4. Spain
    • 7.3.4.1. Spain Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.4.2. Key Country Dynamics
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Reimbursement Scenario
    • 7.3.4.5. Competitive Scenario
  • 7.3.5. France
    • 7.3.5.1. France Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.5.2. Key Country Dynamics
    • 7.3.5.3. Regulatory Framework
    • 7.3.5.4. Reimbursement Scenario
    • 7.3.5.5. Competitive Scenario
  • 7.3.6. Italy
    • 7.3.6.1. Italy Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.6.2. Key Country Dynamics
    • 7.3.6.3. Regulatory Framework
    • 7.3.6.4. Reimbursement Scenario
    • 7.3.6.5. Competitive Scenario
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.7.2. Key Country Dynamics
    • 7.3.7.3. Regulatory Framework
    • 7.3.7.4. Reimbursement Scenario
    • 7.3.7.5. Competitive Scenario
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.8.2. Key Country Dynamics
    • 7.3.8.3. Regulatory Framework
    • 7.3.8.4. Reimbursement Scenario
    • 7.3.8.5. Competitive Scenario
  • 7.3.9. Norway
    • 7.3.9.1. Norway Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.9.2. Key Country Dynamics
    • 7.3.9.3. Regulatory Framework
    • 7.3.9.4. Reimbursement Scenario
    • 7.3.9.5. Competitive Scenario
• 7.4. Asia Pacific
  • 7.4.1. Asia-Pacific Renal Biomarkers Market, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Japan Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.4.2.2. Key Country Dynamics
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Scenario
    • 7.4.2.5. Competitive Scenario
  • 7.4.3. China
    • 7.4.3.1. China Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.4.3.2. Key Country Dynamics
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Scenario
    • 7.4.3.5. Competitive Scenario
  • 7.4.4. India
    • 7.4.4.1. India Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.4.4.2. Key Country Dynamics
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Scenario
    • 7.4.4.5. Competitive Scenario
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.4.5.2. Key Country Dynamics
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Reimbursement Scenario
    • 7.4.5.5. Competitive Scenario
  • 7.4.6. Thailand
    • 7.4.6.1. Thailand Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.4.6.2. Key Country Dynamics
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Reimbursement Scenario
    • 7.4.6.5. Competitive Scenario
  • 7.4.7. Australia
    • 7.4.7.1. Australia Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.4.7.2. Key Country Dynamics
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Reimbursement Scenario
    • 7.4.7.5. Competitive Scenario
• 7.5. Latin America
  • 7.5.1. Latin America Renal Biomarkers Market, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.5.2.2. Key Country Dynamics
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Scenario
    • 7.5.2.5. Competitive Scenario
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.5.3.2. Key Country Dynamics
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Scenario
    • 7.5.3.5. Competitive Scenario
• 7.6. MEA
  • 7.6.1. MEA Renal Biomarkers Market, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. South Africa Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.6.2.2. Key Country Dynamics
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Scenario
    • 7.6.2.5. Competitive Scenario
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Saudi Arabia Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.6.3.2. Key Country Dynamics
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Scenario
    • 7.6.3.5. Competitive Scenario
  • 7.6.4. UAE
    • 7.6.4.1. UAE Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.6.4.2. Key Country Dynamics
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Scenario
    • 7.6.4.5. Competitive Scenario
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Renal Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.6.5.2. Key Country Dynamics
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Scenario
    • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
  • 8.2.1. New Biomarkers Launch
  • 8.2.2. Partnerships
  • 8.2.3. Acquisition
  • 8.2.4. Collaboration
  • 8.2.5. Funding
• 8.3. Key Company Market Share Analysis, 2024
• 8.4. Company Heat Map Analysis
• 8.5. Company Profiles
  • 8.5.1. Thermo Fisher Scientific Inc.
    • 8.5.1.1. Company Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Biomarkers Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.2. Siemens Healthineers AG
    • 8.5.2.1. Company Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Biomarkers Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. BioPorto Diagnostics A/S
    • 8.5.3.1. Company Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Biomarkers Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. SEKISUI Medical Co., Ltd
    • 8.5.4.1. Company Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Biomarkers Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. BioMerieux SA
    • 8.5.5.1. Company Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Biomarkers Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. SphingoTec GmbH
    • 8.5.6.1. Company Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Biomarkers Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Randox Laboratories Ltd
    • 8.5.7.1. Company Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Biomarkers Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Beckman Coulter Inc.
    • 8.5.8.1. Company Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Biomarkers Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. QIAGEN N.V.
    • 8.5.9.1. Company Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Biomarkers Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. EKF Diagnostics Holdings plc
    • 8.5.10.1. Company Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Biomarkers Benchmarking
    • 8.5.10.4. Strategic Initiatives